Phase 1 Vasculitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older
- You have been diagnosed with one of the following conditions: Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome, Systemic Scleroderma, Dermatomyositis (with a specific positive antibody test result), or a type of blood vessel inflammation called ANCA-associated vasculitis (including GPA, MPA, or EGPA) — diagnosed using specific medical standards
- Your disease is considered active enough to meet specific scoring thresholds set for each condition (confirm with trial site for the exact score required for your condition)
- You are generally well enough to carry out light activity or normal daily tasks (rated 0 or 1 on a standard health performance scale)
- Your blood counts meet minimum levels — for example, haemoglobin of at least 60g/L and platelets of at least 30×10⁹/L
- Your heart is pumping well enough, with no major abnormalities on a heart tracing (ECG)
- Your kidneys are working at a sufficient level (eGFR of at least 30 mL/min/1.73m²)
- Your liver test results are within acceptable ranges
- Your lungs are functioning above minimum required levels on breathing tests
- You are able to have blood taken or cells collected without major complications
- If you could become pregnant, you have a negative pregnancy test and agree to use effective contraception during the trial and for one year after receiving the treatment
- You (or your guardian) fully understand the trial and are willing to sign a consent form agreeing to take part
Who may not be able to join:
- You have previously received a type of treatment called CAR T cell therapy
- You have serious heart, liver, lung, blood, hormonal, or other organ problems where the risks of joining the trial are considered greater than the possible benefits (as judged by the medical team)
- You have an active or uncontrolled infection that needs treatment throughout the body within one week before assessment
- You have previously had a stem cell transplant or organ transplant (except cornea or hair transplants), or have had a significant transplant rejection reaction within two weeks before assessment
- You have active Hepatitis B, Hepatitis C, HIV, syphilis, or an active cytomegalovirus (CMV) infection based on blood tests
- You have received a live vaccine within four weeks before assessment
- You have a positive pregnancy test
- You have or have had a cancer diagnosis, with some exceptions such as certain fully treated skin cancers, early-stage cervical cancer, or certain prostate or breast cancers that have been treated with surgery (confirm with trial site)
- You have taken part in another clinical trial within the three months before assessment
- The medical team considers participation to be unsuitable for you for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Liyun Zhang, M.D, Shanxi Bethune Hospital
Phone: 13834547708
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Adverse events after CD19 CAR-T cells infusion [Safety and Tolerability]; Obtain the maximum tolerated dose of CD19 CAR-T cells[Safety and Tolerability]; Efficacy of CAR-T cell preparations in Refractory systemic lupus erythematosus [Effectiveness]; Efficacy of CAR-T cell preparations in Refractory Systemic scleroderma [Effectiveness]; Efficacy of CAR-T cell preparations in Refractory Sjogren's syndrome [Effectiveness]; Efficacy of CAR-T cell preparations in Refractory dermatomyositis [Effectiveness]; Efficacy of CAR-T cell preparations in Refractory The antineutrophil cytoplasmic...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.